Both primary and all key secondary efficacy endpoints showed statistically significant improvements with oral Zeposia versus placebo at Week 10 and Week 52
No new safety signals were observed with Zeposia in the True North study
Results to be presented in two late-breaking oral presentations at UEG Week Virtual 2020
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today announced detailed results from True North, a pivotal, placebo-controlled Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy in adult patients with moderate to severe ulcerative colitis (UC). True North met both primary endpoints, demonstrating highly statistically significant and clinically meaningful results for clinical remission compared to placebo at induction at Week 10 (18.4% versus 6.0%; p-value